Incorporating Palliative Care Improved Radiation Treatment for Bone Metastases
October 7th 2015A novel program combining radiation oncology with palliative care in patients with painful bone metastases increased the use of proven treatments while maintaining pain management, decreased palliative radiation use, and decreased hospital length of stay.
Challenges of Rural Cancer Care in the United States
Rural cancer patients often face substantial barriers to receiving optimal treatment, including availability of cancer care providers, distance to services, lack of public transportation, financial barriers, and limited access to clinical trials. However, a number of promising approaches may address some of these challenges.
Should Response to Preoperative Therapy Guide Local Management in Node-Positive Breast Cancer?
September 15th 2015Current data challenge the statement that recommendations for postmastectomy radiotherapy should be based on the highest clinical or pathologic stage. Instead, data suggest that in a majority of patients, the pathologic stage after neoadjuvant chemotherapy carries more prognostic value.
Country Docs With City Technology Can Address Rural Cancer Care Disparities
September 15th 2015As technology has affected every segment of society, we in the oncology community have a responsibility to make every effort to utilize these advances to enable the broadest possible outreach to our patient population in a continual process of quality improvement.
Please! Tell Me How I Can Help You!
September 2nd 2015No matter how much education my staff and I participate in, we will never cover every single possible adverse event that an individual may experience. And in some cases, when a patient can't explain their symptoms, we can be at a loss as to how to help them.
Radium-223 in Bone-Metastatic Prostate Cancer: Current Data and Future Prospects
July 15th 2015This article will describe the historic background of Ra-223; outline the clinical studies which led to phase III trials of this agent; highlight key results of these phase III studies; and explore possible future directions for use of Ra-223 and other alpha particles-both in prostate cancer and for management of other diseases.